AstraZeneca to acquire TeneoTwo to expand blood cancer pipeline

5 July 2022

In a move to further expand its blood cancer research portfolio, Anglo-Swedish pharma major AstraZeneca (LSE: AZN) today announced an agreement to acquire USA-based biotech TeneoTwo, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma.

The acquisition of TNB-486 aims to accelerate the development of this potential new medicine for B-cell hematologic malignancies, including diffuse large B-cell lymphoma and follicular lymphoma. Building on the success of its own drug Calquence (acalabrutinib), TNB-486 further diversifies AstraZeneca’s hematology pipeline that spans multiple therapeutic modalities and mechanisms to address a broad spectrum of blood cancers. Calquence alone generated revenues of $1.2 billion last year.

Financial considerations

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK